A carregar...
Sunitinib side effects as surrogate biomarkers of efficacy
With the proliferation of treatment options for the management of metastatic renal cell carcinoma (mRCC) over the past decade, predictive markers of response to therapy are becoming increasingly important. Sunitinib is commonly used in the first-line treatment of mRCC. Common mechanism-based adverse...
Na minha lista:
| Publicado no: | Can Urol Assoc J |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Canadian Medical Association
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5215302/ https://ncbi.nlm.nih.gov/pubmed/28096937 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5489/cuaj.4315 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|